Project Grant HT94252310880
Award Date
9/1/23
Completion Date
8/31/27
Dollars Obligated
$6.3M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
The Defense Health Agency awarded Massachusetts General Hospital a $368,238 project grant under the Military Medical Research and Development program (CFDA 12.420) from September 1, 2023 through August 31, 2026. The grant will fund research to determine if microbiome-derived cell fragments in the brain accelerate transition from traumatic brain injury to Alzheimer's disease or related dementias. As a leading academic medical center, Massachusetts General Hospital will leverage its expertise in...
Brigham & Women's Hospital Inc. was awarded a $379,876 project grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 1, 2023 through August 31, 2026 to investigate whether microbiome-derived cell fragments in the brain can accelerate the transition from traumatic brain injury to Alzheimer's disease or related dementias. As the direct awardee, Brigham & Women's Hospital will leverage...
Brigham & Women's Hospital Inc. was awarded a $596,016 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from September 1, 2023 to August 31, 2027 to investigate environmental and gut-brain axis determinants of cognitive outcomes in Parkinson's disease. As the primary awardee, Brigham & Women's Hospital will leverage its expertise in biomedical research and healthcare services...
This Project Grant award of $6,964,861.00 from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports a longitudinal research study on psychological health care for the military. The key products and services to be delivered include: Conducting prospective, longitudinal follow-ups of 3,360 previous clinical trial participants treated for PTSD, sleep disorders, or chronic pain, as well as 4,112 combat soldiers previously assessed before and...
The Defense Health Agency awarded Brigham & Women's Hospital Inc. a $253,636 Project Grant under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from July 1, 2023 to June 30, 2025 to investigate the role of the secreted factor CTHRC1 in the pathogenesis of tuberous sclerosis complex. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public health care...
This Project Grant award of $2,384,097, provided by the Defense Health Agency through the Military Medical Research and Development (CFDA 12.420) federal grant program, is funding a hybrid experimental clinical trial to determine the optimal sequencing of interventions to maximize the effectiveness of PTSD treatment. The primary awardee, The University of Texas Health Science Center at San Antonio, will conduct this research with a planned completion date of August 2028. The project involves two...
The Defense Health Agency awarded a $1,318,799.00 Project Grant to Brigham & Women's Hospital Inc. in Boston, MA on June 15, 2023 under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "THE BRIDGE PROJECT: BROADENING THE REACH OF IMAGING, DIAGNOSTICS, AND GENETIC EVALUATION", will fund research and development to transform healthcare for U.S. military service members and the public through innovative medical solutions for the battlefield and...
This $2,763,615 federal Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports a randomized controlled trial of brief prolonged exposure therapy for injured individuals admitted to a Level I trauma center. The goal is to evaluate the effectiveness of this approach in preventing post-traumatic stress disorder (PTSD) in this patient population. The 4-year study is being conducted by the Baylor Research Institute, a non-profit...
The U.S. Defense Health Agency awarded a $2,534,532 Project Grant to Rush University Medical Center to evaluate evidence-based options for initial PTSD treatment non-responders. This grant is funded through the Military Medical Research and Development program (CFDA 12.420), which supports a comprehensive range of biomedical research initiatives aimed at improving health outcomes for military service members, veterans, and the broader public. The award has a performance period of September 1,...
This Project Grant award for $4,208,345, awarded on September 30, 2024 by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports a hybrid 1 effectiveness-implementation trial of partner-assisted prolonged exposure for PTSD. The research will be conducted by the Regents of the University of Minnesota, a prominent non-profit land-grant research institution, over a performance period of 4 years ending on September 29, 2028. The goal of this...